Non-mutant recombinant Protein A ligand, native sequence, ~50 mg/mL IgG capacity.
rSPA is Repligen's most advanced non-mutant recombinant Protein A ligand, delivering performance equivalent to native Protein A with superior economics and supply-chain security. It contains the identical amino-acid sequence and molecular mass as native Protein A from S. aureus, manufactured by animal-free E. coli fermentation, and achieves roughly 50 mg/mL binding capacity for human IgG across three isotypes.
The ligand maintains >95% purity by SEC and endotoxin levels ≤1.0 EU/mg, meeting stringent pharmaceutical requirements for reproducibility, binding capacity and specificity. Most of the world's commercial monoclonal antibodies are purified using native and recombinant Protein A ligands manufactured by Repligen.
- Biopharma
- Pharmaceutical